Hutch Humphreys is an experienced regulatory professional with over 15 years of increasing responsibility for programs in all phases of product development, from pre-IND to NDA submission and post-approval lifecycle management. Prior to Endeavor Biomedicines, Humphreys was at Amylin Pharmaceuticals, Therapeutics, Inc., Samumed, LLC, and Intercept Pharmaceuticals, all in San Diego, CA, serving in expanding regulatory leadership roles for compounds in a wide variety of therapeutic areas, including metabolism/endocrinology, dermatology, rheumatology, oncology and pulmonology. Humphreys is also an adjunct faculty member at KGI, teaching a course on current issues in regulatory affairs. Humphreys earned a BS in Chemical Engineering at the University of Kansas. After college, he spent five years as a nuclear-trained submarine officer in the US Navy, serving onboard the USS Helena, homeported in Pearl Harbor, HI, and San Diego, CA. Following military service, he attended KGI, earning a Master of Bioscience degree prior to entering the pharmaceutical industry.